{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-26-000662","form_type":"8-K","ticker":"ARTL","cik":"0001621221","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.602932+00:00","generated_at":"2026-05-15T07:01:51.316933+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artelo Biosciences regains Nasdaq compliance; monitored for one year","bullets":["Nasdaq confirmed compliance with Equity Rule (≥$2.5M stockholders' equity) and Annual Meeting Rule.","Subject to mandatory panel monitor through April 6, 2027; re-deficiency could trigger delisting.","CEO cites focus on ART27.13 (cancer cachexia) Phase 2 data, ART26.12 (neuropathic pain), and partnerships.","Common stock trades on Nasdaq under ticker ARTL."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-26-000662","json":"https://secwatch.observer/filing/0001640334-26-000662.json","markdown":"https://secwatch.observer/filing/0001640334-26-000662.md","text":"https://secwatch.observer/filing/0001640334-26-000662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000662/0001640334-26-000662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000662/artl_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:01:51.316933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}